RNA Pol II Inhibitor-Bacteria is under clinical development by Hamlet Pharma and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RNA Pol II Inhibitor-Bacteria’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RNA Pol II Inhibitor-Bacteria overview
The drug candidate is under development for the treatment of inflammation and unspecified infectious diseases. It acts by targeting RNA polymerase II (RNA Pol II).
Hamlet Pharma overview
Hamlet Pharma is a pharmaceutical company developing drugs for the treatment of cancer and infections. The company develops Human Alpha-lactalbumin Made Lethal to Tumour cells, a tumoricidal protein-lipid complex, formed using two generally regarded as safe molecules present in human milk. Its therapeutic agent kills various cancer cells without harming the healthy tissues and can be used for the treatment of dermatological conditions and various types of cancer such as bladder, colon cancer, and brain tumor, among others. The company works in partnership with various pharmaceutical companies to develop drugs for the treatment of cancer. Hamlet Pharma is headquartered in Lund, Sweden.
For a complete picture of RNA Pol II Inhibitor-Bacteria’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
